SECOND OPINION SERVICES
FOR CANCER PATIENTS

Not every cancer case needs a second opinion. For straightforward early-stage cancers with clear standard treatment, the first plan is usually the right one. Where second opinions consistently add value is at the decision points — moments when the choice ahead will shape outcomes for months or years. These include diagnosis confirmation in unusual or borderline cases, decisions about surgery versus neoadjuvant therapy, choice of first-line systemic therapy in advanced disease, decisions after disease progression, evaluation for clinical trials, and any situation where the patient or family feels the picture has not been fully explained.

Diagnostic confirmation Pathology and imaging review can confirm or reclassify the diagnosis. In rare cancers, sarcomas, lymphomas, and cancer of unknown primary, expert pathology review meaningfully changes the diagnosis in a noticeable proportion of cases. Misclassified tumours are treated incorrectly, and a structured review at a high-volume centre is one of the most valuable steps a family can take early. Staging accuracy Staging drives treatment intent — curative versus palliative, surgical versus systemic, single modality versus combined. A second look at imaging, additional scans where indicated, and review of nodal or metastatic findings can change the stage and therefore the entire treatment direction. Biomarker and molecular review Many advanced cancers now have actionable findings on NGS, IHC, or specific biomarker panels. A second opinion often identifies missing biomarker testing — BRCA, HER2, MSI/dMMR, PD-L1, KRAS, EGFR, ALK, ROS1, NTRK, and others — that could change first-line therapy. CancerFax sees this regularly: the right test was simply not done before treatment started. Treatment plan optimisation The same diagnosis can have multiple legitimate treatment pathways. A second opinion can highlight modern combinations, neoadjuvant strategies, de-escalation options, less toxic alternatives, or upgraded regimens that were not the first choice locally. This is especially valuable in advanced cancers where first-line decisions strongly influence later options. Clinical trial identification Clinical trials are often the most meaningful option for patients with advanced disease, but matching is complex. A second opinion at an experienced centre can identify relevant trials in the patient's region or internationally, including KRAS, HER2, ADC, bispecific, cell therapy, and immunotherapy combination studies. Goals of care alignment In advanced cancer, treatment intensity should match goals of care. A structured review can help families align on what is realistic, what trade-offs are involved, and where best supportive care or hospice may be more appropriate than further aggressive therapy. This is rarely a comfortable conversation but is one of the most valuable functions of a thoughtful second opinion.

Online or remote second opinion A specialist or multidisciplinary team reviews medical records, imaging, and pathology, then provides a written report and sometimes a video consultation. No travel is required. This is the most common format internationally and is well suited for diagnosis confirmation, treatment plan review, and biomarker discussion. In-person second opinion The patient travels to the consulting hospital for a physical examination, review, and sometimes additional investigations. This is appropriate when surgery is being considered, when imaging needs to be repeated, or when in-person evaluation will meaningfully change the recommendation. Multidisciplinary tumour board review The case is discussed by a panel of specialists — medical oncology, surgical oncology, radiation oncology, pathology, radiology, and where relevant interventional, transplant, or genetics teams. This format is particularly valuable for complex, advanced, or unusual cases where a single-specialist opinion may miss multidisciplinary nuances.

Case organisation — diagnosis, treatment history, biomarkers, and current status are organised into a clear case summary for specialist review. Specialist matching — the case is shared with experienced oncologists or multidisciplinary teams suited to the diagnosis, in India, China, Germany, the United States, and other regions. Report interpretation — second opinion findings are explained in plain language so patients understand what changes and what stays the same. Next-step coordination — if the second opinion suggests biomarker testing, trial enrolment, or treatment elsewhere, CancerFax helps plan the next step responsibly. Continuity with home team — second opinion findings are shared back with the treating oncologist where helpful, so care remains coordinated rather than fragmented.

Second opinion costs vary widely depending on whether the review is online or in-person, single-specialist or multidisciplinary, and the country and centre involved. Online second opinions are generally the most accessible, with structured reports typically returned within five to fifteen working days once all reports are submitted. Multidisciplinary tumour board reviews take longer due to scheduling. In-person second opinions add travel, accommodation, and sometimes additional investigations to the total. CancerFax helps patients understand realistic ranges before committing. Final cost depends on the consulting centre and any additional investigations recommended.

In some situations — acute leukaemia, aggressive lymphomas, oncologic emergencies, spinal cord compression, or rapidly progressing disease — treatment cannot wait. A second opinion is still possible in parallel through structured remote review, but it should not delay urgent care. CancerFax helps families understand when to move quickly with the local team and pursue review alongside, versus when there is genuine room to consider options before committing. Honest framing here matters more than completeness.

Frequently Asked Questions

Answers to common questions from patients and families.